Background
==========

Breast cancer is the most common female malignancy in both developing and developed countries \[[@b1-medscimonit-24-4776]\]. According to a 2012 report of World Health Organization (WHO), breast cancer is the leading cause of death among women worldwide, accounting for 23% of all cancer deaths \[[@b2-medscimonit-24-4776]\]. There were 1.7 million newly diagnosed breast cancer cases in 2012 (the second most common cancer overall). Nearly 60% of deaths due to breast cancer occur in developing countries \[[@b3-medscimonit-24-4776]\]. Although the mortality rate of breast cancer has decreased over the past 2 decades, the risk of breast cancer recurrence is still high. About one-third of patients with early-stage breast cancer experienced disease recurrence after initial diagnosis \[[@b4-medscimonit-24-4776]\]. Considering the large affected population worldwide, it is important to find biomarkers to identify patients with high risk of recurrence.

ROCK2 is one of the most important targets for the Rho subfamily of small GTPases \[[@b5-medscimonit-24-4776],[@b6-medscimonit-24-4776]\]. It is activated by interaction with Rho GTPases and modulates a series of processes related to cytoskeletal rearrangement, such as focal adhesion formation, cell motility, and tumor cell invasion \[[@b5-medscimonit-24-4776],[@b7-medscimonit-24-4776]\]. Accumulating evidence links ROCK2 to the progression and pathogenesis of several human tumors \[[@b8-medscimonit-24-4776],[@b9-medscimonit-24-4776]\]. The expression of ROCK2 in colorectal tumor tissues was significantly higher than in non-cancerous tissues, and elevated ROCK2 level was closely associated with tumor invasion \[[@b10-medscimonit-24-4776]\]. It has been reported that the upregulation of ROCK2 promoted metastasis, proliferation, and invasion of gastric cancer cells \[[@b9-medscimonit-24-4776]\]. Previous studies showed that ROCK2 genetic polymorphisms were associated with disease development. Of particular interest is that a study reported that Thr431Asn polymorphism in ROCK2 protein could be a risk factor for breast cancer metastases \[[@b11-medscimonit-24-4776]\], indicating that ROCK2 may be of great value in predicting poor prognosis in patients with breast cancer.

In this study, we examined the association of ROCK2 expression level with clinicopathological features by using the TCGA breast cancer dataset and tissue array.

Material and Methods
====================

Patients and tissue samples
---------------------------

The study was approved by the Research Ethics Committee of Tongxu County People's Hospital, Henan Province, China. Informed consent was obtained from all of the patients. For immunohistochemical analysis, a tissue array including 40 adjacent non-cancerous breast tissues and 40 breast cancer tissues was obtained from Xi'an Alenabio Co, LTD (Cat No. BR804a). Patients who had received radiotherapy or chemotherapy before the surgery were excluded from the study. Clinical information was collected from the TCGA dataset, including 999 breast cancer tissues.

Immunohistochemical staining and analysis
-----------------------------------------

The paraffin-embedded tissues in the tissue array were deparaffinized with xylene and rehydrated, and then were stained using the DAKO EnVision System (Dako Diagnostics, Switzerland). The tissue slides were incubated using a 1: 50 dilution of the primary antibody against ROCK2 overnight (rabbit polyclonal antibody, ab71598, Abcam Co., Ltd., UK) at 4°C. After washing with PBS, peroxidase-labeled polymer and substrate-chromogen were used to visualize the staining of the protein of interest.

The immunolabeling of cancer cells was evaluated. Cytoplasmic staining was regarded as positive signals. The semi-quantitative scoring of the expression intensity in each sample was calculated by multiplying the staining intensity (0 points=no staining, 1 point=mild staining, 2 points=moderate staining, and 3 points=strong staining) and the percentage of stained cells (0 points=\<5%), 1 point=6--25%), 2 points=(26--50%), 3 points=51--75%, and 4 points=\>75%).

Statistical analysis
--------------------

SPSS 22.0 software (SPSS, Inc, IL, USA) was used for statistical analyses. The association of ROCK2 expression with clinicopathological characteristics was analyzed using Pearson chi-squared tests or Fisher exact test. The Kaplan-Meier method was used to analyze overall survivals. Cox proportional hazard regression models were used to perform univariate and multivariate analysis comparisons. When the P-value was \<0.05, differences were considered statistically significant.

Results
=======

ROCK2 expression was associated with clinicopathological features of breast cancer patients
-------------------------------------------------------------------------------------------

We used tissue array to investigate whether the protein level of ROCK2 was correlated with the clinical features of breast invasive cancer specimens. The expression and localization of ROCK2 in 40 breast cancer specimens and paired non-cancerous breast specimens were analyzed by immunohistochemistry. Many cancer specimens were strongly stained in the cytoplasm ([Figure 1A](#f1-medscimonit-24-4776){ref-type="fig"}), whereas weak or negative staining was observed in paired adjacent normal tissues ([Figure 1B](#f1-medscimonit-24-4776){ref-type="fig"}). The average immunoreactivity scores were significantly higher in breast cancer tissues (n=40) when compared with non-cancerous breast tissues (n=40) ([Figure 1C](#f1-medscimonit-24-4776){ref-type="fig"}) (IRS: Cancer=5.25±2.10 *vs.* Normal=3.83±1.06, P\<0.01, *t* test).

We analyzed immunohistochemical results in combination with the information of tumor node metastasis (TNM) classification from tissue array. Subgroup analyses were performed according to the ROCK2 staining scores. We categorized the samples into low- (IRS ≤4) and high- (IRS \>4) expression subgroups. We found no relationship between ROCK2 expression and patient age or pathological grade ([Table 1](#t1-medscimonit-24-4776){ref-type="table"}). However, a positive relationship between the occurrence of breast cancer and ROCK2 expression was found. Of 40 breast cancer tissues, 20 (50%) were defined as high-expression, while only 4 out of 40 (10%) were considered as high-expression in the non-cancerous specimens group (*P*\<0.001, [Table 1](#t1-medscimonit-24-4776){ref-type="table"}). Similar associations were also observed between ROCK2 expression and several tumor characteristics ([Table 1](#t1-medscimonit-24-4776){ref-type="table"}), including clinical stage (I--II *vs.* III--IV, *P*\<0.001), tumor stage (T1--T3 *vs.* T4, *P*=0.047), and lymph node metastasis (N0--N1 *vs.* N2, *P*=0.020). Furthermore, using ROCK2 mRNA data extracted from the TCGA 999 primary breast cancer dataset, we found that ROCK2 transcription level was significantly correlated with tumor staging (T1--T3 *vs.* T4,*P*=0.030).

Prognostic implications of ROCK2 expression in breast cancer
------------------------------------------------------------

Kaplan-Meier survival analyses together with univariate and multivariate analysis were performed using the TCGA dataset (n=999) to assess the prognostic implications of ROCK2. Patients were divided into a ROCK2 high-expression group and a low-expression group using median expression of ROCK2 as the cut-off value.

Kaplan-Meier method was used to analyze the relationship between overall survivals and ROCK2 expression in breast cancer patients. Patients with higher ROCK2 expression levels in tumors showed shorter overall survival as compared to those with lower expression (P=0.037, [Figure 2](#f2-medscimonit-24-4776){ref-type="fig"}).

Univariate analysis showed that clinical stage (*P*\<0.001) and lymph node metastasis stage (*P=*0.005) were potential clinical factors affecting overall survival rates in patients ([Table 2](#t2-medscimonit-24-4776){ref-type="table"}). Furthermore, patients were assigned into low- or high-ROCK2 expression group based on ROCK2 mRNA expression level. Receiver operating characteristic (ROC) curve analysis was performed. The optimal cut-off value was set as 876.62. Notably, the overall survival rate was significantly different between the high- and low-ROCK2 expression groups. Patients with high ROCK2 expression in tumor specimen appeared to have a worse prognosis (HR 1.564; 95%; CI; 1.079--2.269; *P*\<0.018, [Table 2](#t2-medscimonit-24-4776){ref-type="table"}). Further multivariate analysis suggested that ROCK2 expression level (HR, 1.706; 95%CI: 1.144--2.544; *P*=0.009) and clinical stage (HR, 1.923;95%CI, 1.102--3.356; *P*=0.001) were factors correlated with overall survival ([Table 2](#t2-medscimonit-24-4776){ref-type="table"}), indicating that ROCK2 and clinical stage might be prognostic biomarkers for breast cancer.

Discussion
==========

It has been shown that ROCK2 is associated with cancer development in several reports. Functional studies showed that ROCK2 promoted invasion and metastasis of colon, liver, and lung cancer cells \[[@b12-medscimonit-24-4776]--[@b14-medscimonit-24-4776]\]. ROCK2 mediated the invasion of colon cancer through the regulation of MMP-13 and MMP-2 \[[@b10-medscimonit-24-4776]\]. The activation of ROCK-2/moesin cascade mediated VEGF-C to promote endometrial cancer cell invasion \[[@b15-medscimonit-24-4776]\]. Li et al. reported that ROCK2 functions as a key factor in the regulation of breast cancer cell invasion and motility \[[@b16-medscimonit-24-4776]\]. In contrast, ROCK 2 knockdown decreased the invasion and motility capacity of breast cancer cells \[[@b17-medscimonit-24-4776]\]. Even though the molecular function of ROCK2 has been intensively studied, the clinical relevance of ROCK2 expression is unclear.

The present study explored the difference in ROCK2 level between breast cancer tissues and adjacent non-cancerous breast tissues. Analysis of the TCGA database and tissue array showed that ROCK2 expression level in cancer tissues was significantly higher than in paired adjacent normal tissues. Moreover, both ROCK2 mRNA and protein level were associated with pT stage of breast cancer. Patients with advanced tumor stage have higher ROCK2 level. Our study demonstrated that only 28.6% of stage I and II cancer patients had high ROCK2 expression in breast cancer tissues. In contrast, the ratio of high ROCK2 level in stage III and IV phases was 100% in our cohort. Furthermore, high ROCK2 immunoreactivity was more common in tumor samples from pT4- (*vs.* pT1--pT3) and pN2- (*vs.* pN0--pN1) stage patients. Our study shows that ROCK2 might act as an oncogene in the development of breast cancer, which is consistent with the findings that ROCK2 may favor cancer cell proliferation or metastasis.

Breast cancer is a highly heterogeneous disease \[[@b18-medscimonit-24-4776]\]. Individuals with breast cancer may have different responses to treatment. At present, due to the development of surgical techniques, adjuvant chemotherapy, radiotherapy, and targeted therapy, the survival rate of breast cancer patients has greatly improved. Although the incidence of metastasis and recurrence is still negligible after standard treatment, the current prognostic biomarkers are not satisfactory. Therefore, efforts to identify biomarkers for breast cancer patient prognosis and clinical therapy recommendation are still ongoing. The present study suggests that ROCK2 is such a factor. Using Cox proportional hazards model and Kaplan-Meier plots, we found that ROCK2 expression levels were significantly associated with overall survival. Patients with higher ROCK2 expression in tumor tissues had shorter overall survival. More importantly, ROCK2 expression and clinical stage appeared to be independent risk factors for overall survival as indicated by multivariate analysis. Our study suggests that ROCK2 and clinical stage can be used as biomarkers for prognosis of breast cancer patients. These preliminary findings encourage us to pursue further studies with larger sample sizes.

Conclusions
===========

We showed that expression level of ROCK2 was higher in breast cancer tissue compared with paired adjacent breast specimens. ROCK2 level in the breast cancer tissue was associated with overall survival. In the univariate and multivariate Cox regression analysis, high ROCK2 expression and clinical stage predicted poor prognosis after treatment.
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![Immunohistochemical staining for ROCK2 in breast invasive cancer tissue and normal breast tissues (original magnifications ×100 and ×400). (**A**) Strong ROCK2 staining was observed in the cytoplasm of tumor cells. Image at high magnification is shown in the right. The red arrow indicates positively-stained tumor cells. (**B**) Negative staining of ROCK2 expression was observed in the normal breast tissues. (**C**) Immunoreactivity score in cancer tissues was significantly higher than in normal tissues (Cancer=5.25±2.10 *vs.* Normal=3.83±1.06). \*\* Indicates *P*\<0.01.](medscimonit-24-4776-g001){#f1-medscimonit-24-4776}

![Kaplan-Meier survival curves of overall survival for ROCK2 expression in breast invasive cancer.](medscimonit-24-4776-g002){#f2-medscimonit-24-4776}

###### 

Association of ROCK2 expression with clinicopathologic characteristics in patients with breast invasive cancer.

  Clinical feature              IRS of ROCK2 in our cohort   ROCK2 expression in TCGA datebase                                                 
  ----------------------------- ---------------------------- ----------------------------------- ------------ --------- ----- ---------------- -------
  Tissue                                                                                                                                       
   Cancer                       40                           20 (50.0)                           20 (50.0)    \<0.001   999   934.27±568.90    --
   Adjacent normal              40                           36 (90.0)                           4 (10.0)               --    --               
  Age (years)                                                                                                                                  
   \<50                         30                           15 (50.0)                           15 (50.0)    1.000     268   987.76±555.61    0.072
   ≥50                          10                           5 (50.0)                            5 (50.0)               731   914.60±572.84    
  Pathological grade                                                                                                                           
   ≤2                           35                           17 (48.6)                           18 (51.4)    1.000     --    --               --
   \>2                          2                            1 (50.0)                            1 (50.0)               --    --               
  Clinical stage                                                                                                                               
   I--II                        28                           20 (71.4)                           8 (28.6)     \<0.001   742   930.09±583.73    0.931
   III--IV                      12                           0 (0.0)                             12 (100.0)             238   926.40±505.17    
  Tumor stage                                                                                                                                  
   T1--T3                       35                           20 (57.1)                           15 (42.9)    0.047     960   929.83±572.44    0.030
   T4                           5                            0 (0.0)                             5 (100.0)              36    1111.45±425.10   
  Lymph node metastasis stage                                                                                                                  
   N0--N1                       34                           20 (58.8)                           14 (41.2)    0.020     804   926.89±571.04    0.619
   N2                           6                            0 (0.0)                             6 (100.0)              178   950.44±546.25    
  pM stage                                                                                                                                     
   M0                           40                           20 (50.0)                           20 (50.0)    --        859   966.35±572.05    0.621
   M1                           --                           --                                  --                     15    890.28±420.17    

"−" -- means a lack of relative information of patients in our cohort.

###### 

Prognostic value of ROCK2 expression for the overall survival by Cox proportional hazards model.

  Variables                                                                               Univariate analysis    Multivariate analysis                          
  --------------------------------------------------------------------------------------- ---------------------- ----------------------- ---------------------- -------
  Age (\<50 *vs.* ≥50)                                                                                           0.100                                          
  Clinical stage (I--II *vs.* III--IV)                                                    2.038 (1.374--3.023)   \<0.001                 1.923 (1.102--3.356)   0.021
  pT stage (T1--T3 *vs.* T4)                                                              1.877 (0.994--3.547)   0.052                                          
  pN stage (N0--N1 *vs.* N2)                                                              1.941 (1.228--3.068)   0.005                                          0.810
  ROCK2 expression (low *vs.* high)[\*](#tfn2-medscimonit-24-4776){ref-type="table-fn"}   1.564 (1.079--2.269)   0.018                   1.706 (1.144--2.544)   0.009

Low and high ROCK2 expression was determined based on the ROC curve analysis using the mRNA expression level of TCGA breast cancer dataset.

The cut-off value was set as 876.62.
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